BioNote, Inc.

As of June 30, 2026, BioNote, Inc. carries a market capitalization of 458.93B, placing it among publicly traded companies globally. Its enterprise value stands at 93.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioNote, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, BioNote, Inc. has 100.75M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.63, and the price-to-book ratio stands at 0.30.

As of June 30, 2026, BioNote, Inc. trades at an EV/EBITDA multiple of 3.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 93.87B versus a market cap of 458.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioNote, Inc. maintains a current ratio of 18.53, meaning it holds 18.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.21, indicating conservative leverage, while an interest coverage ratio of 151.05 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioNote, Inc. posted a negative return on equity (ROE) of -7.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.53, reflecting losses generated across the asset base. The company generates approximately 384.51M in revenue per employee across its workforce of 328.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.96 indicates how many times BioNote, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioNote, Inc. recorded 11.96B in income tax expense. The company reported a pretax loss of -113.73B and -125.69B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, BioNote, Inc.'s stock has declined approximately 17.59% over the past 52 weeks. The 50-day moving average sits at 4,734.00, while the 200-day moving average is 5,002.93.

Over the twelve months ended June 30, 2026, BioNote, Inc. generated 126.41B in revenue and converted that into -125.69B in net income, yielding earnings per share of -1,247.78. EBITDA reached 30.36B, while operating income came in at 20.63B.

As of June 30, 2026, BioNote, Inc. holds 368.27B in cash and equivalents against 3.21B in total debt, resulting in a net debt position of -56.61B. Total book value stands at 1.55T, with working capital of 413.62B providing operational flexibility.

BioNote, Inc. produced 45.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.07B in capital expenditures, free cash flow totaled 41.48B - equivalent to 412.13 per share.

Over the twelve months ended June 30, 2026, BioNote, Inc. posted a gross margin of 56.55, reflecting its pricing power and cost economics. The operating margin of 16.32 and net profit margin of -99.43 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, BioNote, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.04, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.91, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioNote, Inc. shareholders.

As of June 30, 2026, BioNote, Inc. has an Altman Z-Score of 5.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.